New hope for high-risk prostate cancer: drug duo after surgery may stop recurrence
NCT ID NCT07282197
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase 2 trial tests whether adding darolutamide (a pill that blocks male hormones) to standard hormone therapy after prostate removal can keep cancer from coming back in high-risk patients. About 40 men will take the combination for 12 months and be followed for 2 years. The main goal is to see how many remain free of biochemical recurrence (a rise in PSA levels).
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Darolutamide (a drug that blocks androgen receptors) plus androgen-deprivation therapy (ADT, hormone therapy that lowers testosterone)
- What this could lead to
- If successful, this could offer a new way to delay prostate cancer recurrence after surgery, potentially reducing the need for more aggressive treatments.
- What could go wrong
- This is a small, early-phase trial with only 40 participants and no comparison group, so results may not apply broadly. Side effects from darolutamide and hormone therapy can include fatigue, hot flashes, and cardiovascular risks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University First Hospital
Beijing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can surgery boost control of spread prostate cancer?
- Can a new tracer light up hidden prostate cancer?
- Could deep breaths before surgery ward off Post-Op confusion?
- A second look: MRI screening may spot hidden prostate cancers
- Can precision protons spare the bowel in prostate cancer?
- AI coaches doctors on cancer risk talks